ZERO IS POSSIBLE: A majority of people on HEMLIBRA had zero bleeds requiring treatment, regardless of their age, dosing option, or inhibitor status in the pivotal HAVEN 1-4 trials*
PERCENTAGE OF PEOPLE WITH ZERO BLEEDS REQUIRING TREATMENT
HAVEN 1
ADULTS AND YOUNG ADULTS WITH FACTOR VIII INHIBITORS
of people taking HEMLIBRA ONCE A WEEK had 0 bleeds (22/35)
VS
of people taking bypassing agents to treat bleeds on-demand (no prophylaxis) had 0 bleeds (1/18)
HAVEN 3
ADULTS AND YOUNG ADULTS WITHOUT FACTOR VIII INHIBITORS
of people taking HEMLIBRA ONCE A WEEK had 0 bleeds (20/36)
of people taking HEMLIBRA ONCE EVERY 2 WEEKS had 0 bleeds (21/35)
VS
of people taking factor VIII to treat bleeds on-demand (no prophylaxis) had 0 bleeds (0/18)
HAVEN 4
ADULTS AND YOUNG ADULTS WITH OR WITHOUT FACTOR VIII INHIBITORS
of people taking HEMLIBRA ONCE EVERY 4 WEEKS had 0 bleeds (23/41)
Adults: 18 years or older. | Young adults (adolescents): 12 years to less than 18 years.
The average number of treated bleeds per year (ABR, annualized bleed rate)*†
- HAVEN 1: once every week 2.9, no prophylaxis 23.3
- HAVEN 3: once every week 1.5, once every 2 weeks 1.3, no prophylaxis 38.2
- HAVEN 4: once every 4 weeks 2.4
The median time on HEMLIBRA for HAVEN 1: 29 weeks (once every week), 24 weeks (no prophylaxis); HAVEN 3: 30 weeks (once every week), 31 weeks (once every 2 weeks), 24 weeks (no prophylaxis); HAVEN 4: 26 weeks (once every 4 weeks). A median is a numeric middle. That means that in a list of numbers, the median is the number in the middle. A median is a numeric middle. That means that in a list of numbers, the median is the number in the middle.
*The need to treat was determined by the individual or the study physician.
†ABRs shown are for treated bleeds.
We’re committed to the hemophilia A community
For years, Genentech has studied HEMLIBRA in diverse populations, impacting the lives of >30,000 people worldwide,‡ including >8,600 in the US.§ Click here to explore data in our younger populations.
‡Number of people with hemophilia A treated with HEMLIBRA worldwide as of June 2025.
§Number of people with hemophilia A treated with HEMLIBRA in the US as of August 2025.
Feel the difference one change makes
Decrease in average number of treated bleeds per year (ABR, annualized bleed rate) in a study of adults and young adults
Adults: 18 years or older | Young adults (adolescents): 12 years to less than 18 years
Without factor VIII inhibitors: HAVEN 3 study
People who switched from taking factor VIII to prevent bleeds (prophylaxis) to HEMLIBRA had 68% fewer bleeds that needed treatment.
Median observation period: 34 weeks (HEMLIBRA prophylaxis) and 30 weeks (previous factor VIII prophylaxis).
With factor VIII inhibitors: HAVEN 1 study
People who switched from taking bypassing therapy to prevent bleeds (prophylaxis) to HEMLIBRA had 79% fewer bleeds that needed treatment.
Median observation period: 30 weeks (HEMLIBRA prophylaxis) and 32 weeks (previous bypassing therapy prophylaxis).
A median is a numeric middle. That means that in a list of numbers, the median is the number in the middle.
Make a choice for your joint health
People taking HEMLIBRA for at least 24 weeks (HAVEN 3) saw a 95% reduction in target joint bleeds that needed treatment.
ADULTS AND YOUNG ADULTS WITHOUT FACTOR VIII INHIBITORS: HAVEN 3
HEMLIBRA ONCE A WEEK
REDUCTION IN TARGET JOINT BLEEDS THAT NEEDED TREATMENT
VS NO PROPHYLAXIS | 36 PEOPLE
HEMLIBRA ONCE EVERY 2 WEEKS
REDUCTION IN TARGET JOINT BLEEDS THAT NEEDED TREATMENT
VS NO PROPHYLAXIS | 35 PEOPLE
A POST HOC, DESCRIPTIVE STUDY OF TARGET JOINT HEALTH IN PEOPLE TAKING HEMLIBRA LONG-TERM: HAVEN 3
HEMLIBRA ONCE A WEEK
OF TARGET JOINTS WERE RESOLVED IN PATIENTS TAKING HEMLIBRA
These data are from 97 people who reported a combined total of 238 target joints before starting HEMLIBRA and were then on HEMLIBRA for a median of 262 weeks
What is a target joint?
Target joints were defined as major joints (eg, hip, elbow, wrist, shoulder, knee, and ankle) in which ≥3 bleeds occurred over a 24-week period.
What is a resolved target joint?
A target joint is resolved if it had 2 or fewer bleeds during 52 weeks of HEMLIBRA treatment.
What is a post hoc, descriptive study?
A post hoc analysis is an analysis of clinical trial data that was not planned before data collection was started and it is not designed to prove cause and effect. In a descriptive study, researchers are simply looking at what happened in a clinical trial, without determining a definitive benefit. Therefore, conclusions should not be drawn based on this information.
“One thing I’ve learned through this experience on HEMLIBRA was how much time I used to spend thinking about my joints and paying attention to them. It has allowed me to spend less time treating bleeds and more time doing the things I enjoy.”
—Matt, takes HEMLIBRA for hemophilia A without inhibitors, Washington
Individual results may vary. Not all patients in the clinical trials had zero bleeds. See results for clinical trial patients with or without factor VIII inhibitors at the top of this page.
When starting HEMLIBRA, a “loading dose” is taken once weekly for 4 weeks. After that, HEMLIBRA offers 3 regular dosing options: once weekly, once every 2 weeks, or once every 4 weeks. Talk to your doctor about dosing.
See How Clinical Trials Make a Difference for the Community
“I have always been willing to participate in studies and trials if I’m able to, so it was natural for me to tell my hematologists about the HAVEN 1 trial for HEMLIBRA.”
–Harvey, takes HEMLIBRA, participated in the HAVEN 1 trial
We Just Dropped the Beat—About Our Data
We teamed up with Tamar, a musician on HEMLIBRA, to create a song all about the HEMLIBRA data. So turn up the volume, we know it will have your head bobbing in zero seconds.